Cantor Fitzgerald’s Foghorn Therapeutics FHTX Stock Holding History

Cantor Fitzgerald’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-150,000	Closed	-$705K	–	430
2025 Q2	$705K	Buy	+150,000	New	+$627K	0.01%	189

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Cantor Fitzgerald's FHTX Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Foghorn Therapeutics (FHTX) in Q3 2025, closing a stake of 150,000 shares — an estimated $705K sold.

Cantor Fitzgerald first reported a position in FHTX in Q2 2025 and held it in 1 quarter. The position peaked at $705K in Q2 2025. 88 funds tracked by Wall St. Rank hold FHTX as of Q3 2025.

Cantor Fitzgerald reported no remaining Foghorn Therapeutics position as of Q3 2025 after selling out during the quarter.
Cantor Fitzgerald sold 150,000 Foghorn Therapeutics shares in Q3 2025, an estimated $705K.
Cantor Fitzgerald first reported a position in Foghorn Therapeutics in Q2 2025 and held it in 1 quarter.
Cantor Fitzgerald's Foghorn Therapeutics position peaked at $705K in Q2 2025.
88 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.